Get the Stockscreener App
1.45
4.61%
-0.07
After Hours:
1.47
0.02
+1.38%
Metagenomi Therapeutics Inc stock is traded at $1.45, with a volume of 258.28K.
It is down -4.61% in the last 24 hours and down -17.14% over the past month.
Metagenomi Therapeutics Inc formerly, Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A, Refractory Hypertension, Cardiovascular diseases, and others.
See More
Previous Close:
$1.52
Open:
$1.52
24h Volume:
258.28K
Relative Volume:
0.74
Market Cap:
$54.44M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.84%
1M Performance:
-17.14%
6M Performance:
-22.87%
1Y Performance:
-39.33%
1-Day Range:
$1.44
$1.54
1-Week Range:
$1.39
$1.59
52-Week Range:
$1.23
$3.95
Metagenomi Therapeutics Inc Stock (MGX) Company Profile
Name
Metagenomi Therapeutics Inc
Sector
Industry
Phone
(510) 871-4880
Address
5959 HORTON STREET, EMERYVILLE
Compare MGX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGX
Metagenomi Therapeutics Inc
|
1.45 | 57.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Metagenomi Therapeutics Inc Stock (MGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-24 | Initiated | H.C. Wainwright | Buy |
| May-02-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Mar-05-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-24 | Initiated | Chardan Capital Markets | Buy |
| Mar-05-24 | Initiated | JP Morgan | Overweight |
| Mar-05-24 | Initiated | Jefferies | Buy |
| Mar-05-24 | Initiated | TD Cowen | Outperform |
| Mar-05-24 | Initiated | Wells Fargo | Overweight |
View All
Metagenomi Therapeutics Inc Stock (MGX) Latest News
Is Metagenomi Therapeutics (NASDAQ:MGX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Head to Head Analysis: Acusphere (OTCMKTS:ACUS) and Metagenomi (NASDAQ:MGX) - Defense World
Xeris Biopharma (NASDAQ:XERS) and Metagenomi (NASDAQ:MGX) Critical Comparison - Defense World
Metagenomi (NASDAQ:MGX) and UCB (OTCMKTS:UCBJY) Critical Survey - Defense World
These two noteworthy penny stocks can do wonders! Here's more insights into Alto Ingredients, Metagenomi and others - MSN
Aug Sentiment: Why Metagenomi Inc stock could benefit from AI revolutionAnalyst Upgrade & Daily Volume Surge Trade Alerts - moha.gov.vn
Resistance Check: Should I add Metagenomi Inc stock to my portfolioJuly 2025 Catalysts & Reliable Volume Spike Trade Alerts - baoquankhu1.vn
Metagenomi changes name, advances hemophilia A gene therapy program By Investing.com - Investing.com Nigeria
Metagenomi advances gene editing therapies into 2025 - MSN
Metagenomi changes name, advances hemophilia A gene therapy program - Investing.com
Metagenomi Therapeutics Rebrands to Emphasize Therapeutic Focus - TipRanks
Metagenomi to submit IND in Q4 2026 to advance MGX-001 into first human studies - TipRanks
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights Recent Business Milestones and 2026 Corporate Outlook - The Manila Times
Metagenomi Announces Corporate Name Change to Metagenomi Therapeutics, Inc. and Highlights ... - bdtonline.com
Gainers Report: Is Metagenomi Inc stock dividend yield sustainableFed Meeting & Weekly Top Performers Watchlists - moha.gov.vn
Is Metagenomi Inc. stock dividend yield sustainableWide Width Options & HOKA model picks for your routine - ulpravda.ru
Operating cash flow per share of Metagenomi, Inc. – NASDAQ:MGX - TradingView — Track All Markets
VIX Spike: Is Metagenomi Inc. stock dividend yield sustainableTrend Reversal & Expert Curated Trade Setups - Улправда
Patterns Watch: Is Metagenomi Inc. stock undervalued vs historical averages2025 Historical Comparison & Consistent Profit Trading Strategies - Улправда
Is Metagenomi Inc. stock positioned well for digital economy2025 Stock Rankings & AI Forecasted Entry and Exit Points - Улправда
Is Metagenomi Inc. stock a defensive play in 2025Earnings Miss & Weekly High Momentum Picks - Улправда
Will Metagenomi Inc. stock attract ESG investors2025 Short Interest & Free AI Powered Buy and Sell Recommendations - Улправда
How interest rate cuts could boost Metagenomi Inc. stock2025 Trading Volume Trends & High Accuracy Investment Entry Signals - ulpravda.ru
Market Overview: Is Metagenomi Inc. stock supported by innovation pipelineWeekly Profit Summary & Expert-Curated Trade Recommendations - ulpravda.ru
Is Metagenomi Inc. stock in correction or buying zoneWeekly Investment Report & Capital Efficiency Focused Ideas - Улправда
Oklahoma City NewsThe OklahomanMetagenomi, Inc.Common Stock (Nasdaq:MGX) Detailed Stock Data - FinancialContent
Is Metagenomi Inc. stock supported by innovation pipelineAnalyst Upgrade & Entry Point Confirmation Alerts - ulpravda.ru
Why Metagenomi Inc. stock attracts global investorsJuly 2025 Summary & Long-Term Capital Growth Ideas - ulpravda.ru
Why Cloudflare, Inc. stock attracts strong analyst attention - Улправда
Is Metagenomi Inc. stock attractive after correctionHigh Beta Stocks & Maximize ROI With Proven Growth Stocks - Улправда
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Fed Impact: Is Metagenomi Inc stock undervalued vs historical averagesCEO Change & Reliable Breakout Forecasts - moha.gov.vn
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates - MSN
Head to Head Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) vs. Metagenomi (NASDAQ:MGX) - Defense World
Short Interest in Metagenomi, Inc. (NASDAQ:MGX) Grows By 27.1% - Defense World
Exit Recap: Is Metagenomi Inc stock supported by innovation pipeline2025 Trading Volume Trends & Fast Moving Stock Trade Plans - moha.gov.vn
Irish Jian, Metagenomi CEO, sells $2899 in MGX stock By Investing.com - Investing.com UK
Irish Jian, Metagenomi CEO, sells $2899 in MGX stock - Investing.com
Metagenomi Earnings Notes - Trefis
CEO Moves: Can Metagenomi Inc stock weather global recession2025 Key Lessons & Stepwise Entry/Exit Trade Alerts - moha.gov.vn
Why analysts upgrade Metagenomi Inc. stock2025 Price Targets & High Win Rate Trade Alerts - Улправда
Is Metagenomi Inc. stock recession proofJuly 2025 Summary & High Accuracy Investment Entry Signals - Улправда
Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Thomas Brian C. sells $6786 in Metagenomi (MGX) stock By Investing.com - Investing.com Australia
Irish Jian, Metagenomi CEO, sells $2838 in MGX stock - Investing.com India
Metagenomi CFO Wapnick sells $2792 in shares By Investing.com - Investing.com Australia
Irish Jian, Metagenomi CEO, sells $2838 in MGX stock By Investing.com - Investing.com Australia
Metagenomi general counsel Wein sells $352 in stock By Investing.com - Investing.com Nigeria
Thomas Brian C. sells $6786 in Metagenomi (MGX) stock - Investing.com
Metagenomi Therapeutics Inc Stock (MGX) Financials Data
There is no financial data for Metagenomi Therapeutics Inc (MGX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):